Jürgen Mestan

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl

Ellen Weisberg, Paul W. Manley, Werner Breitenstein et al. · Cancer Cell · 2005 · 1.5K citations · Full text

Molecular Pharmacology, Mutant Bcr-abl, Medicine +5

<i>In vitro</i> Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants

Thomas O’Hare, Denise K. Walters, Eric P. Stoffregen et al. · Cancer Research · 2005 · 1K citations · Full text

<i>S6K1</i> ^−/− / <i>S6K2</i> ^−/− Mice Exhibit Perinatal Lethality and Rapamycin-Sensitive 5′-Terminal Oligopyrimidine mRNA Translation and Reveal a Mitogen-Activated Protein Kinase-Dependent S6 Kinase Pathway

Mario Pende, Sung Hee Um, Virginie Mieulet et al. · Molecular and Cellular Biology · 2004 · 731 citations · Full text

Skp2 is oncogenic and overexpressed in human cancers

Matthias Gstaiger, Richard C. Jordan, Megan S. Lim et al. · Proceedings of the National Academy of Sciences · 2001 · 501 citations · Full text

Antiviral effects of recombinant tumour necrosis factor in vitro

Jürgen Mestan, W. Digel, Sibylle Mittnacht et al. · Nature · 1986 · 387 citations

Antiviral Effects, Immunology, Antiviral Therapy +5